This section captures fundamental shipment identification and product metadata essential for traceability and regulatory compliance. Accurate completion is critical for initiating investigation and disposition workflows.
Master Air Waybill (MAWB) Number
House Air Waybill (HAWB) Number
Carrier Name
Transport Mode
Air Freight
Ocean Freight
Road Transport
Intermodal
Flight Number
Vessel Name & Voyage Number
Vehicle Registration Number
Describe Intermodal Journey Sequence
Origin Airport/Port Code
Destination Airport/Port Code
Shipment Departure Date/Time
Shipment Arrival Date/Time
Product Batch/Lot Details
Product Name | Batch/Lot Number | Quantity (Units) | Dosage Form | Strength/Potency | Manufacturer Name | ||
|---|---|---|---|---|---|---|---|
A | B | C | D | E | F | ||
1 | COVID-19 mRNA Vaccine | VAC-2024-7890 | 5000 | Injectable Solution | 100 mcg/dose | BioPharma Inc. | |
2 | Influenza Vaccine | FLU-2024-3210 | 2500 | Injectable Solution | 45 mcg/dose | VaxGlobal Ltd. | |
3 | |||||||
4 | |||||||
5 | |||||||
6 | |||||||
7 | |||||||
8 | |||||||
9 | |||||||
10 |
Total Declared Value of Shipment
Required Storage Temperature Range
Temperature Set Point
Packaging Configuration
Active Refrigerated Container
Passive Thermal Shipper
Insulated Box with Phase Change Material
Dry Ice Shipper
Liquid Nitrogen Dewar
Container ID/Serial Number
Thermal Shipper Model
Number of PCM Packs Used
Dry Ice Weight (kg)
Liquid Nitrogen Fill Level (%)
Shipper/Consignor Name
Consignee Name
Associated Documentation References
This section documents the digital temperature monitoring ecosystem, sensor performance, and precise thermal exposure metrics. The data captured here forms the technical foundation for deviation assessment and determines the scope of product impact evaluation.
Temperature Monitoring Device Serial Number
Sensor Type
Single-use PDF Logger
Multi-use Bluetooth Logger
Real-time IoT Sensor (4G/5G)
Real-time IoT Sensor (Satellite)
Wired Thermocouple Array
Is the temperature monitoring device calibrated and within valid certification period?
Explain calibration status and impact on data reliability:
Was the temperature data successfully downloaded/retrieved from the device?
Describe data retrieval failure and alternative evidence:
Temperature Excursion Start Date/Time
Temperature Excursion End Date/Time
Total Thermal Exposure Duration (minutes)
Maximum Temperature Recorded (°C)
Minimum Temperature Recorded (°C)
Mean Kinetic Temperature (MKT) During Excursion (°C)
Which temperature threshold(s) were breached? (Select all that apply)
Upper Warning Limit
Upper Action Limit
Lower Warning Limit
Lower Action Limit
Critical Threshold - Product Integrity Compromised
Did the temperature monitoring device issue real-time alerts during the excursion?
Describe alert recipients, response time, and immediate actions taken upon alert:
Explain why alerts were not generated or received:
Ambient Environmental Conditions During Incident
Upload Photograph of Temperature Logger Display/Screenshot at Time of Discovery
Upload Complete Temperature Data File (PDF/CSV/XML format)
Are there any gaps or anomalies in the temperature data record?
Describe data gaps, their duration, and potential causes:
This section evaluates the potential impact on product quality, safety, and efficacy based on stability profiles, visual inspection, and scientific risk assessment. The findings here directly influence quarantine decisions and regulatory reporting obligations.
Has a visual inspection of the product been completed?
Visual Inspection Findings (Select all observed anomalies)
No visible defects - product appears normal
Physical damage to primary packaging
Condensation inside vials/containers
Discoloration of product
Particulate matter visible
Cracked or compromised containers
Label damage or illegibility
Explain why visual inspection was not performed and schedule for completion:
Time Out of Refrigeration (TOR) - Total Accumulated Minutes
Is there available stability data covering the observed temperature excursion conditions?
Reference stability study protocols, batch numbers, and conclusions that support product integrity:
Explain the absence of stability data and the implications for risk assessment:
Product Potency Risk Assessment Matrix - Rate each factor based on observed conditions
Very Low Risk | Low Risk | Moderate Risk | High Risk | Critical Risk | |
|---|---|---|---|---|---|
Severity of temperature deviation from specification | |||||
Duration of thermal exposure | |||||
Product sensitivity to temperature (based on known stability profile) | |||||
Integrity of primary packaging post-incident | |||||
Phase of product lifecycle (clinical vs commercial) | |||||
Availability of supportive stability data |
Overall Product Integrity Confidence Level (1 = No Confidence, 5 = Full Confidence)
Has the manufacturer or Marketing Authorization Holder been notified of the incident?
Provide notification timestamp, contact person, and preliminary guidance received:
Explain the delay and planned notification schedule:
Is regulatory authority notification required based on risk assessment?
Which regulatory agencies require notification? (Select all applicable)
Health Authority of Destination Country
Health Authority of Origin Country
WHO (for global health programs)
EMA (European Medicines Agency)
FDA (Food and Drug Administration)
Other National Regulatory Authority
Will product samples be retained for analytical testing?
Specify sample quantity, storage location, testing laboratory, and planned test protocols:
Preliminary Product Disposition Recommendation
Release for Distribution (No Impact)
Release with Restrictions (Conditional Approval)
Quarantine Pending Further Investigation
Reject - Initiate Destruction Protocol
Await Manufacturer/Regulatory Guidance
Upload Supporting Documentation (Stability Reports, Manufacturer Correspondence, Photographs)
This section documents immediate containment measures, quarantine logistics, and remedial shipment arrangements to maintain supply chain continuity while ensuring compromised product does not reach patients.
Immediate Containment Actions Taken Upon Discovery (Select all applicable)
Physically segregated affected pallets
Applied 'QUARANTINE - DO NOT USE' labels
Updated inventory management system status
Notified warehouse security
Restricted access to quarantine zone
Initiated temperature-controlled storage in segregated area
Documented initial discovery timestamp and personnel
Quarantine Location (Warehouse Zone/Bay Number)
Is the quarantine area under continuous temperature monitoring?
Describe alternative monitoring arrangements and risk mitigation:
Is a replacement shipment required to fulfill customer orders?
Replacement Freight Dispatch Details
Replacement AWB Number | Replacement Carrier Name | Planned Dispatch Date/Time | Expedited Shipping Service | New Temperature Monitoring Device ID | Enhanced Monitoring Confirmed | ||
|---|---|---|---|---|---|---|---|
A | B | C | D | E | F | ||
1 | 157-12345679 | Emergency Pharma Freight | 12/19/2024, 2:00 PM | Next Flight Out (NFO) | TMD-2024-8848 | ||
2 | |||||||
3 | |||||||
4 | |||||||
5 | |||||||
6 | |||||||
7 | |||||||
8 | |||||||
9 | |||||||
10 |
Has the consignee/customer been notified of the incident and potential delivery delay?
Provide notification timestamp, method, contact person, and customer response:
Incident Cost Tracking & Financial Impact
Cost Category | Quantity/Count | Unit Cost | Total Cost | Insurance Claimable | ||
|---|---|---|---|---|---|---|
A | B | C | D | E | ||
1 | Compromised Product Value | 5000 | $45.50 | $227,500.00 | ||
2 | Replacement Freight Cost | 1 | $8,500.00 | $8,500.00 | ||
3 | Emergency Storage/Handling | 72 | $150.00 | $10,800.00 | ||
4 | Testing & Analysis | 3 | $2,500.00 | $7,500.00 | ||
5 | $0.00 | |||||
6 | $0.00 | |||||
7 | $0.00 | |||||
8 | $0.00 | |||||
9 | $0.00 | |||||
10 | $0.00 |
Root Cause Analysis - Preliminary Assessment
Preventive Actions Implemented to Avoid Recurrence (Select all applicable)
Enhanced pre-shipment equipment checks
Upgraded thermal packaging specifications
Revised standard operating procedures
Additional staff training scheduled
Implemented redundant temperature monitoring
Route optimization to minimize exposure
Supplier/carrier performance review initiated
Is a formal Corrective and Preventive Action (CAPA) investigation required?
CAPA Reference Number
This final section requires dual-authority approval to formally close the incident report and authorize final product disposition. Both signatories attest that all investigations, risk assessments, and regulatory obligations have been satisfactorily completed according to organizational quality standards.
Executive Summary of Incident, Investigation, and Final Disposition Decision
Final Product Disposition Decision
Approved for Distribution - No Quality Impact
Approved for Distribution with Conditions
Rejected - Quarantine for Destruction
Rejected - Return to Manufacturer
Pending - Awaiting External Guidance
Have all regulatory notification obligations been fulfilled?
Describe pending notifications and completion timeline:
Has the incident been formally documented in the quality management system?
Explain QMS documentation status and planned completion:
Head of Global Logistics - Digital Signature
Head of Global Logistics - Name (Printed)
Head of Global Logistics - Approval Timestamp
Quality Control Officer - Digital Signature
Quality Control Officer - Name (Printed)
Quality Control Officer - Approval Timestamp
I confirm that all information provided in this incident report is accurate and complete to the best of my knowledge, and that all necessary investigations, risk assessments, and corrective actions have been conducted according to applicable quality standards and regulatory requirements.
Additional Comments or Special Instructions
Should this incident be escalated to executive management review?
Rationale for executive escalation:
To configure an element, select it on the form.